Elderly patients with renal cell carcinoma (RCC) treated with first-line pazopanib survived longer than those who received sunitinib, according to an analysis involving >1,000 individuals. Pazopanib treatment also resulted in lower costs and utilization. Participants with RCC were ≥65 years of age and started first-line treatment with either pazopanib (n=522) or sunitinib (n=522). Investigators looked at overall survival, costs, and utilization. Among the results:

• The group taking pazopanib survived an average of 18.2 months, vs 14.6 months in the contingent receiving sunitinib.
• All-cause costs were ~$8,800 and ~$10,400, respectively.
• Inpatient costs were ~$1,500 and ~$2,500, respectively.
• Inpatient admissions and lengths of inpatient stay were lower in the pazopanib group.